San Antonio Breast Cancer Symposium 2007—Adjuvant endocrine therapy update: ATAC 100 highlights
2008
Adjuvant Endocrine Therapy Update: Highlights from the ATAC Trial
Editorial
Evidence: moderate
Author Information
Author(s): Joy Anil A.
Primary Institution: Department of Oncology, University of Alberta, and Cross Cancer Institute
Conclusion
The ATAC trial shows that anastrozole is more effective than tamoxifen for postmenopausal women with hormone receptor-positive breast cancer.
Supporting Evidence
- Anastrozole showed improved disease-free survival compared to tamoxifen.
- At 5 years, the time to recurrence was lower for anastrozole than for tamoxifen.
- Anastrozole had a lower incidence of endometrial cancer compared to tamoxifen.
Takeaway
This study found that a medicine called anastrozole works better than another medicine called tamoxifen for women with a certain type of breast cancer.
Methodology
Follow-up data from the ATAC trial were analyzed with a median follow-up of 100 months.
Limitations
No single ideal treatment strategy has emerged, and many questions remain about the best approach.
Participant Demographics
Postmenopausal women with hormone receptor-positive breast cancer.
Statistical Information
P-Value
p = 0.01
Confidence Interval
0.61 to 0.94
Statistical Significance
p = 0.01
Want to read the original?
Access the complete publication on the publisher's website